SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF EPRATUZUMAB IN JAPANESE PATIENTS WITH MODERATE-TO-SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM A PHASE 1/2 STUDY

被引：1
|
作者：
Yamamoto, J. [1 ]
Lledo-Garcia, R. [2 ]
Tsuru, T. [3 ]
Tanaka, Y. [4 ]
Koike, T. [5 ]
机构：
[1] UCB Pharma, Tokyo, Japan
[2] UCB Pharma, Slough, Berks, England
[3] Med Co LTA, PS Clin, Fukuoka, Japan
[4] Univ Occupat & Environm Hlth, Kitakyushu, Fukuoka 807, Japan
[5] NTT Sapporo Med Ctr, Sapporo, Hokkaido, Japan
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2014年 / 73卷
关键词：
D O I：
10.1136/annrheumdis-2014-eular.1754
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0383
引用
收藏
页码：526 / 526
页数：1
相关论文
共 50 条
  • [41] Pharmacokinetics, Safety, and Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 1, Single- and Multiple-Dose Study
    Zheng, Min
    Chen, Xiang
    Wang, Feng
    Chen, Jisu
    Jackson, Kimberley
    Yang, Fan
    Payne, Christopher
    Li, HongYing
    Wang, YiHui
    Xiao, ZiPei
    Zheng, Jie
    [J]. ADVANCES IN THERAPY, 2023, 40 (09) : 3804 - 3816
  • [42] Pharmacokinetics, Safety, and Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 1, Single- and Multiple-Dose Study
    Min Zheng
    Xiang Chen
    Feng Wang
    Jisu Chen
    Kimberley Jackson
    Fan Yang
    Christopher Payne
    HongYing Li
    YiHui Wang
    ZiPei Xiao
    Jie Zheng
    [J]. Advances in Therapy, 2023, 40 : 3804 - 3816
  • [43] Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus Results of a phase I, placebo-controlled, double-blind, dose-escalation study
    McBride, Jacqueline M.
    Jiang, Jenny
    Abbas, Alexander R.
    Morimoto, Alyssa
    Li, Jing
    Maciuca, Romeo
    Townsend, Michael
    Wallace, Daniel J.
    Kennedy, William P.
    Drappa, Jorn
    [J]. ARTHRITIS AND RHEUMATISM, 2012, 64 (11): : 3666 - 3676
  • [44] Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus (vol 60, pg 5397, 2021)
    Furie, Richard A.
    Bruce, Ian N.
    Dorner, Thomas
    Leon, Manuel Gustavo
    Leszczynski, Piotr
    Urowitz, Murray
    Haier, Birgit
    Jimenez, Teri
    Brittain, Claire
    Liu, Jiajun
    Barbey, Catherine
    Stach, Christian
    [J]. RHEUMATOLOGY, 2022, 62 (01) : 486 - 486
  • [45] Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial
    Igarashi, Atsuyuki
    Kato, Takeshi
    Kato, Mai
    Song, Michael
    Nakagawa, Hidemi
    [J]. JOURNAL OF DERMATOLOGY, 2012, 39 (03): : 242 - 252
  • [46] PHARMACOKINETICS OF SIFALIMUMAB AND TARGET MODULATION OF A TYPE I INTERFERON GENE SIGNATURE IN PATIENTS WITH MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS
    Morehouse, C.
    Brohawn, P.
    Higgs, B.
    Zheng, B.
    Yao, Y.
    Roskos, L.
    Robbie, G.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 946 - 946
  • [47] Efficacy and Safety of Abrocitinib in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN study
    Eichenfield, Lawrence
    Flohr, Carsten
    Sidbury, Robert
    Szalai, Zsuzsanna
    Galus, Ryszard
    Yao, Zhirong
    Takahashi, Hidetoshi
    Barbarot, S. Ebastien
    Feeney, Claire
    Zhang, Fan
    DiBonaventura, Marco
    Rojo, Ricardo
    Valdez, Hernan
    Chan, Gary
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB146 - AB146
  • [48] EFFICACY AND SAFETY OF NIPOCALIMAB IN ADULT PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: DESIGN OF A PHASE 2 STUDY
    Liu-Walsh, F.
    Hartingsveldt, B. V.
    Zuraw, Q.
    Hoffman, R. W.
    Rooney, T.
    Gao, S.
    Karpouzas, G.
    Gordon, R.
    Leu, J. H.
    Calderon, C.
    Zazzetti, F.
    Stevens, A. M.
    Vratsanos, G.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1472 - 1473
  • [49] Efficacy and Safety of Ixekizumab in Chinese Patients With Moderate-to-Severe Plaque Psoriasis: 60-Week Results From a Phase 3 Study
    Li Xia
    Zheng Jie
    Pan WeiLi
    Zheng Min
    Lu Yan
    Li FuQiu
    Ding YangFeng
    Zhang JianZhong
    Li HongYing
    Rui WenLong
    [J]. 国际皮肤性病学杂志（英文）., 2022, 05 (04)
  • [50] Efficacy and safety of ixekizumab in Chinese patients with moderate-to-severe plaque psoriasis: 12-week results from a phase 3 study
    Rui, Wenlong
    Li, Xia
    Zheng, Jie
    Pan, Weili
    Zheng, Min
    Lu, Yan
    Li, Fuqiu
    Ding, Yangfeng
    Zhang, Jianzhong
    Li, Hongying
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB55 - AB55
12345